Aspira Women’s Health Broadens Distribution Reach with BioReference Collaboration

Aspira Bio-analytic women’s health company, Aspira Women’s Health (Nasdaq: AWH), will co-market its ovarian cancer detection test with BioReference®, an OPKO Health company, one of the largest full service specialty laboratories in the United States.

Under terms of the agreement, Aspira and BioReference sales teams will collaborate to sell Ova1Plus to gynecologists and other women’s healthcare providers nationwide.

Highlights

• The collaboration will enable Aspira to provide more physicians and their patients with access to its ovarian cancer risk assessment products.
• The agreement has been structured to support rapid volume growth with sales professionals from both companies working collaboratively to ensure physicians understand the power of Aspira’s products to expand market access and provider adoption.

Aspira views the partnership as the beginning of a “long-term relationship that will accelerate the adoption of Ova1Plus and provide incremental revenues at attractive margins for each company”.